Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-046033
Filing Date
2025-05-20
Accepted
2025-05-20 17:03:48
Documents
46
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241499-10q_lomond.htm   iXBRL 10-Q 540123
2 CERTIFICATION ea024149901ex31-1_lomond.htm EX-31.1 11647
3 CERTIFICATION ea024149901ex31-2_lomond.htm EX-31.2 10791
4 CERTIFICATION ea024149901ex32-1_lomond.htm EX-32.1 7094
  Complete submission text file 0001213900-25-046033.txt   3508373

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cik0001900520-20250331.xsd EX-101.SCH 31519
6 XBRL CALCULATION FILE cik0001900520-20250331_cal.xml EX-101.CAL 23356
7 XBRL DEFINITION FILE cik0001900520-20250331_def.xml EX-101.DEF 169388
8 XBRL LABEL FILE cik0001900520-20250331_lab.xml EX-101.LAB 308526
9 XBRL PRESENTATION FILE cik0001900520-20250331_pre.xml EX-101.PRE 180761
48 EXTRACTED XBRL INSTANCE DOCUMENT ea0241499-10q_lomond_htm.xml XML 294183
Mailing Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901
Business Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901 561 464 2841
Lomond Therapeutics Holdings, Inc. (Filer) CIK: 0001900520 (see all company filings)

EIN.: 872959575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56377 | Film No.: 25969765
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)